Navigation Links
Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
Date:7/21/2011

ion of animals in which a chosen gene is specifically removed or "knocked out" from the pig's genome. In the published example, Sangamo scientists and their collaborators in the laboratory of Prof. Dr. Heiner Niemann of the Institute of Farm Animal Genetics in Germany, knocked out both copies of the 1,3-galactosyl transferase (GGTA-1) gene from pig cells and used these to produce cloned animals that lack the target gene. Knockout of the GGTA-1 gene has been shown to lead to significantly improved organ survival in a pig-to-baboon organ transplantation model.

"Sangamo's mission is to develop novel ZFP Therapeutics to address unmet medical needs and make paradigm-shifting therapeutic solutions a reality," stated Edward Lanphier, Sangamo's president and chief executive officer. "This proof of concept study lays the foundation for the use of our validated ZFP platform technology to modify animal organs for human transplantation."  

Efficient Generation of a Biallelic Knockout in Pigs using Zinc-Finger Nucleases.
Hauschild J, Petersen B, Santiago Y, Queisser AL, Carnwath JW, Lucas-Hahn A, Zhang L, Meng X, Gregory PD, Schwinzer R, Cost GJ, Niemann H.
Proc Natl Acad Sci U S A. 2011 108 (29) 12013-12017.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate the safety and efficacy for the treatment of HIV/AIDS as well as a Phase 1 trial for the treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneratio
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
(Date:9/18/2014)... in the course of a day - car, ... on the chemical industry to turn raw materials ... into valuable chemicals that are the ingredients of ... Sarina, who achieved outstanding progress in driving this ... using light instead of fossil fuels, has won ...
(Date:9/18/2014)... City, MX (PRWEB) September 18, 2014 ... in Mexico City, MX. ASEA is the manufacturer of ... and the skin care product, RENU28. , The ... Regional Vice President Duvan Botero, and ASEA Field Leader ... Samuelson holds a PhD in Atomic/Medical Physics from the ...
(Date:9/17/2014)... , Sept. 17, 2014 The global consumption ... by 2019. Squalene is a natural skin-identical chemical that finds ... personal care, food supplements, pharmaceuticals, and in other applications like ... squalene market has a few major players and is regionally ... Kishimoto Special Liver Oil Co. Ltd. ( Japan ...
Breaking Biology Technology:Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Using solar energy to turn raw materials into ingredients for every day life 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... to Screen Donated Blood for Hepatitis B, as well ... and Semi-Automated Instrument Systems -, SAN DIEGO, Aug. ... that the US Food and Drug Administration,(FDA) has approved ... to screen donated blood for the hepatitis B,virus (HBV). ...
... Stock Exchange Symbol: MS, - Milestone triggers ... - EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... trial has conducted the scheduled interim analysis of ...
... Mentice, Inc. and MATC have,forged a relationship that ... multiple,and mutually beneficial projects to further advance the ... throughout North America., Mentice,s Procedicus VIST Simulator ... physician to gain exposure to routine,and sophisticated procedures. ...
Cached Biology Technology:FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation 2
(Date:9/17/2014)... Calif. (Sept. 17, 2014) A rare genetic disorder known ... to a recent joint investigation by researchers at San ... Diego. In addition to suggesting better treatment options for ... clues into the genetic underpinnings of autism., Jacobsen syndrome ... National Institutes of Health. It occurs in a person ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... African sanctuaries carry drug-resistant, human-associated strains of the bacteria ... chimpanzees could spread to endangered wild ape populations if ... study shows. The study by veterinarians, microbiologists and ... sequencing technology of bacterial genomes used in hospitals to ...
... forget-me-nots have been added to Flora of New Zealand . ... Island during an expedition led by Dr. Carlos A. Lehnebach. These ... the open access journal PhytoKeys . The expedition ... at the Museum of New Zealand Te Papa Tongarew a ...
... faces far greater change and risk of large-scale extinctions than ... the world,s leading marine scientists has warned. The researchers ... UK have compared events which drove massive extinctions of sea ... taking place in the seas and oceans globally today. ...
Cached Biology News:Sanctuary chimps show high rates of drug-resistant staph 2No ordinary forget-me-nots 2Sea life 'facing major shock' 2Sea life 'facing major shock' 3
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... The E. coli protein sample ... to give a consistent pattern when ... rehydration and sample buffer. This sample ... to validate your 2-D system and ...
... Tecans new HydroFlex platform provides ... a range of 96-well format applications, ... and protein arrays, and vacuum filtration-to-waste, ... platforms outstanding on-line control features set ...
Biology Products: